2024
Current Research in Colistin Therapeutic Drug Monitoring – Pre-eliminary Results of Investigator-Initiated Clinical Trial COL-ECMO2022
RYCHLÍČKOVÁ, Jitka a Pavel SUKZákladní údaje
Originální název
Current Research in Colistin Therapeutic Drug Monitoring – Pre-eliminary Results of Investigator-Initiated Clinical Trial COL-ECMO2022
Název česky
Current Research in Colistin Therapeutic Drug Monitoring – Pre-eliminary Results of Investigator-Initiated Clinical Trial COL-ECMO2022
Autoři
Vydání
CZECRIN Annual Research Conference and CONSCIOUS II multiplier event, 2024
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/24:00138115
Organizační jednotka
Lékařská fakulta
ISBN
978-80-280-0588-7
Klíčová slova anglicky
colistin; therapeutic drug monitoring; pharmacokinetics; nvestigator-initiated clinical trial
Změněno: 17. 1. 2025 09:27, Mgr. Tereza Miškechová
Anotace
V originále
Recap the shortcomings in colistin therapeutic drug monitoring (TDM) and summarize lessons learned from several follow-up projects that address these gaps. A literature review on colistin TDM. Development of a method for determining colistin/CMS in three matrices. Short-term stability tests of colistin and CMS in the above matrices. Preliminary results of a prospective, non-randomized, single-center phase IV pharmacokinetic clinical trial to assess the effect of ECMO on the pharmacokinetics of colistin and CMS (COL-ECMO2022 trial). The primary shortcomings in colistin TDM are the lack of a method for routine measurement, insufficient stability data for samples, a limited availability of the population pharmacokinetic models. A simple LC-MS/MS method for the determination of both substrates has been established and validated in the associated laboratory; it is currently the only facility in the Czech Republic capable of determining colistin and CMS in plasma/serum. The total analysis time is 5 minutes. Short-term stability data confirming a relationship between colistin/CMS stability and temperature/temperature and concentration provide valuable input for preanalytical sample processing. 23 Preliminary results of the pharmacokinetic study show a high colistin exposure despite standard dosage use. Colistin AUCSS,24h was 165±128 mg.h/L, cSS corresponds to 6.9±5.3 mg/L. Considering the variable relationship between CMS concentration and achieved colistin concentrations, the determination of colistin itself, especially trough concentration, seems to be crucial; the determination of CMS is not essential. Real-time TDM appears to be a fundamental condition for the rational use of colistin, and the above data helps with practical implementation.
Návaznosti
| LM2023049, projekt VaV |
|